Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies evaluate impact of switching on survival in adjuvant treatment of early breast cancer
January 12th, 2006
Studies presented at the San Antonio Breast Cancer Symposium analyze the AstraZeneca drug Arimidex (anastrozole) in terms of overall survival, recurrence-free survival and safety. Arimidex, an aromatase inhibitor, is the only drug in its class that is approved by the U.S. Food and Drug Administration (FDA) for initial adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women. The full FDA approval status for Arimidex is supported by one of the world's longest running and largest studies of breast cancer treatment after surgery, the Arimidex, Tamoxifen Alone or in Combination (ATAC) Trial. ATAC data demonstrated that...
Source: Women's Health Weekly (2006-01-12)
|
